UK pharma urges regulatory reform, but not too much

Spying a chance to remake the way innovative medicines are regulated in the UK, the British pharmaceutical industry is pressing the government to leverage the benefits of its newly-found independence from the European Union.

A new  report from the Association of the British Pharmaceutical Industry (ABPI) sets out recommendations for boosting the attractiveness of the UK for global life sciences investment.

While new medicines in the UK were formerly reviewed under the auspices of the European Medicines Agency, the country’s departure from the EU has handed responsibility for medicines regulation to the Medicines and Healthcare Products Regulatory Agency (MHRA).